MARKET

SGEN

SGEN

Seagen Inc
NASDAQ
139.17
+1.47
+1.07%
Closed 16:41 10/04 EDT
OPEN
138.53
PREV CLOSE
137.70
HIGH
139.99
LOW
137.65
VOLUME
820.16K
TURNOVER
--
52 WEEK HIGH
192.79
52 WEEK LOW
105.43
MARKET CAP
25.67B
P/E (TTM)
-34.4395
1D
5D
1M
3M
1Y
5Y
'Right Now, You've Still Got To Avoid The Stock,' Jim Cramer Says About This Aerospace Company
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Sherwin-Williams Co (NYSE: SHW) might go lower as the PE (price-to-earnings) multiple is still "way too high" on the stock.
Benzinga · 5d ago
Joe Terranova Is Buying This Stock: Wednesday's CNBC 'Fast Money' Final Trades
CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned. The information is collected and refined using Benzinga Pro’s News Tool. Benzinga Pro users can access this information by using the News tool on any workstation.
Benzinga · 6d ago
Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment
Benzinga · 09/27 15:57
Seagen partners with Zai Lab to introduce cervical cancer drug in China
Seagen (NASDAQ:SGEN) and Zai Lab Limited (<a href="https://seekingalp...
Seekingalpha · 09/27 12:26
Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday
Gainers
Benzinga · 09/27 09:15
Nasdaq Turns Lower; Crude Oil Drops Sharply
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite turning negative on Monday.
Benzinga · 09/26 18:49
Why LAVA Therapeutics Shares Are Trading Higher By 97%, Here Are 49 Stocks Moving In Monday's Mid-Day Session
Gainers
Benzinga · 09/26 18:05
Dow Drops Over 100 Points; Crude Oil Rises Over 1%
U.S. stocks traded mixed midway through trading, with the Dow Jones dropping more than 100 points on Monday.
Benzinga · 09/26 16:10
More
About SGEN
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The Company is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. The Company also develops a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its programs, including ADCETRIS and PADCEV, are based on its antibody-drug conjugate (ADC), technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The Company's approved medicines include ADCETRIS, PADCEV and TUKYSA.

Webull offers kinds of Seagen Inc stock information, including NASDAQ:SGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SGEN stock methods without spending real money on the virtual paper trading platform.